IBRANCE Drug Patent Profile

« Back to Dashboard

When do Ibrance patents expire, and when can generic versions of Ibrance launch?

Ibrance is a drug marketed by Pfizer and is included in two NDAs. There are three patents protecting this drug and two Paragraph IV challenges.

The generic ingredient in IBRANCE is palbociclib. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

DrugPatentWatch^® Generic Entry Outlook for Ibrance

Ibrance was eligible for patent challenges on February 3, 2019.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 8, 2034. This may change due to patent challenges or generic licensing.

There have been forty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are ten tentative approvals for the generic drug (palbociclib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for IBRANCE

US Patents:	3
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	93
Clinical Trials:	128
Patent Applications:	5,881
Drug Prices:	Drug price information for IBRANCE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for IBRANCE
What excipients (inactive ingredients) are in IBRANCE?	IBRANCE excipients list
DailyMed Link:	IBRANCE at DailyMed

See drug prices for IBRANCE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IBRANCE

NDA:

207103

Dosage:

CAPSULE;ORAL

NDA:

212436

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IBRANCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University Medical Center Groningen	Phase 4
Megalabs	PHASE4
AstraZeneca	Phase 1/Phase 2

See all IBRANCE clinical trials

Pharmacology for IBRANCE

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors Kinase Inhibitors

Paragraph IV (Patent) Challenges for IBRANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IBRANCE	Tablets	palbociclib	75 mg, 100 mg and 125 mg	212436	1	2020-11-24
IBRANCE	Capsules	palbociclib	75 mg, 100 mg and 125 mg	207103	12	2019-02-04

US Patents and Regulatory Information for IBRANCE

IBRANCE is protected by three US patents and three FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes					Y
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-003	Nov 1, 2019		RX	Yes	Yes

Expired US Patents for IBRANCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015
Pfizer	IBRANCE	palbociclib	TABLET;ORAL	212436-001	Nov 1, 2019
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015

EU/EMA Drug Approvals for IBRANCE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Ibrance	palbociclib	EMEA/H/C/003853Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist.	Authorised	no	no	no	2016-11-09

International Patents for IBRANCE

When does loss-of-exclusivity occur for IBRANCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Hong Kong

Hungary

Israel

Japan

Lithuania

Mexico

New Zealand

Peru

Poland

Portugal

Russian Federation

Saudi Arabia

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IBRANCE around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	094842
Australia	2014220354
Brazil	112015019508

Supplementary Protection Certificates for IBRANCE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1470124	300863	Netherlands		PRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/16/1147 20161111
1470124	122017000014	Germany		PRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
1470124	PA2017013	Lithuania		PRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109

IBRANCE Market Dynamics, Revenue Trajectory, Patent Exclusivity, and Generic Risk

Last updated: October 23, 2026

IBRANCE, Pfizer’s palbociclib, remains a major CDK4/6 inhibitor in HR-positive, HER2-negative advanced or metastatic breast cancer. Its commercial base is large but mature. Pfizer reported approximately $4.8 billion in IBRANCE revenue in 2024, down from about $5.1 billion in 2022 as competition from Kisqali and Verzenio increased and the product moved closer to generic exposure. The principal long-term risks are erosion of metastatic breast-cancer share, negative adjuvant-trial history, and ANDA-based generic entry after the remaining U.S. patent barriers expire.

What is IBRANCE and how does it generate revenue?

IBRANCE is an oral selective CDK4/6 inhibitor. It blocks cyclin-dependent kinases 4 and 6, reducing retinoblastoma-protein phosphorylation and slowing cell-cycle progression.

The FDA approved IBRANCE in February 2015 for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with letrozole. The label later expanded to include combination use with fulvestrant and treatment of men with HR-positive, HER2-negative advanced or metastatic breast cancer. Premenopausal and perimenopausal patients generally receive ovarian suppression alongside endocrine therapy.[1]

IBRANCE commercial profile

Metric	Position
Active ingredient	Palbociclib
Originator	Pfizer
Drug class	CDK4/6 inhibitor
Primary indication	HR-positive, HER2-negative advanced or metastatic breast cancer
Primary U.S. dosage form	125 mg, 100 mg, and 75 mg capsules; tablets also marketed
Standard schedule	21 days on treatment followed by 7 days off
Principal combinations	Aromatase inhibitor or fulvestrant
U.S. approval	2015
U.S. regulatory pathway	New Drug Application
Biosimilar exposure	None; palbociclib is a small molecule
Main competitive products	Kisqali and Verzenio

The commercial model depends on prolonged use in metastatic disease. Patients can remain on therapy until disease progression or unacceptable toxicity, supporting recurring revenue rather than one-time treatment revenue. Neutropenia is the principal dose-limiting toxicity and can require treatment interruption, dose reduction, or monitoring.[1]

What are Pfizer’s IBRANCE revenues and financial trajectory?

IBRANCE revenue peaked before the CDK4/6 market reached maturity. Pfizer’s reported figures show a gradual decline:

Fiscal year	IBRANCE revenue	Approximate year-over-year change
2021	$5.4 billion	Decline from prior peak
2022	$5.1 billion	About -6%
2023	$4.8 billion	About -6%
2024	$4.8 billion	Approximately flat to slightly lower

Source: Pfizer annual reports and Form 10-K filings.[2-5]

The revenue trajectory reflects several factors:

1. Class competition. Novartis’s Kisqali and Lilly’s Verzenio have taken share in metastatic disease.
2. Treatment differentiation. Kisqali has gained attention from overall-survival data and an FDA approval in early breast cancer. Verzenio has an established adjuvant indication and a different toxicity profile.
3. Mature patient base. IBRANCE already has broad recognition among oncologists and established use in endocrine-based treatment sequences.
4. Lack of adjuvant success. Pfizer’s PALLAS and PENELOPE-B studies did not establish a broad early-breast-cancer indication for palbociclib.[6,7]
5. Upcoming generic pressure. Generic palbociclib will affect price and volume once the relevant U.S. patents and settlements permit commercial entry.

IBRANCE remains financially material to Pfizer. A revenue base near $5 billion means every 10% decline represents roughly $480 million in annual sales exposure before offsetting growth from other products.

When does IBRANCE lose exclusivity?

IBRANCE does not have a single exclusivity date. Its effective loss-of-exclusivity timeline depends on regulatory exclusivity, Orange Book patents, pediatric extensions, ANDA litigation, and settlement terms.

U.S. exclusivity timeline

Protection category	Relevance to IBRANCE
New chemical entity exclusivity	Expired after the initial five-year period
Regulatory indication exclusivity	Limited compared with the remaining patent estate
Composition and drug-product patents	Core barriers to generic approval or launch
Method-of-use patents	May protect specific combinations or treatment uses
Pediatric extension	Can add six months to eligible patent or exclusivity periods
ANDA litigation	Can create a 30-month stay after a Paragraph IV notice and patent suit

Public market references generally place meaningful U.S. generic entry risk around the late 2020s, commonly citing 2027 as the principal commercial risk year. The exact date can differ by patent, dosage form, settlement agreement, and court outcome. Pfizer’s annual filings identify IBRANCE as exposed to patent litigation and future generic competition.[2-5]

What patents protect IBRANCE?

The IBRANCE patent estate includes composition-of-matter, pharmaceutical-composition, crystalline-form, and method-of-use claims. The estate has been built around palbociclib itself, solid-state forms, formulations, and use with endocrine therapies.

Representative U.S. patents associated with the palbociclib product and patent litigation record include:

Patent	Broad protection category	Business relevance
U.S. Patent No. 6,936,612	Palbociclib-related compound and pharmaceutical claims	Foundational early patent family
U.S. Patent No. 8,415,355	Palbociclib-related drug-product or solid-state protection	Important Orange Book and litigation reference
Later Pfizer patent families	Drug product, crystalline form, formulation, and treatment-use claims	Extend barriers beyond the earliest compound patent

Patent scope and expiration must be assessed patent by patent. A patent’s expiration date does not automatically establish the first lawful generic-launch date because an ANDA applicant may challenge validity, enforceability, or infringement before expiry. Conversely, a settlement may allow entry before the latest listed patent expires.

What formulations are protected by IBRANCE patents?

IBRANCE has been marketed in capsule and tablet forms. Formulation and solid-state patents can protect:

• Palbociclib crystalline forms
• Tablet compositions
• Capsule compositions
• Dosage strengths
• Manufacturing processes
• Stability characteristics
• Pharmaceutical combinations with endocrine therapy

Formulation patents are commercially important because an ANDA applicant must demonstrate pharmaceutical equivalence and may need to design around specific claims. They can delay entry even after an early active-ingredient patent expires.

What is the Orange Book status of IBRANCE?

IBRANCE is listed in the FDA Orange Book as a prescription drug product with patent information submitted by Pfizer. The relevant listings can include drug-substance, drug-product, and method-of-use patents.[8]

An ANDA applicant seeking to market generic palbociclib must make a certification for each listed patent:

• Paragraph I: no patent information is listed.
• Paragraph II: the patent has expired.
• Paragraph III: the applicant will wait until patent expiration.
• Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

A Paragraph IV certification can trigger patent litigation by Pfizer. If Pfizer sues within the statutory period, FDA approval may be subject to a 30-month stay, unless the litigation is resolved earlier or the court orders otherwise.

Which companies are challenging IBRANCE patents?

Generic-drug companies have pursued palbociclib through ANDA filings and patent challenges. Public litigation and regulatory records have associated IBRANCE patent disputes with multiple generic manufacturers, including Teva, Apotex, Sun Pharmaceutical Industries, Hetero, Cipla, Amneal, and other applicants across different proceedings.

The strategic question is not only whether a company files a Paragraph IV certification. The decisive issues are:

• Whether Pfizer sues within the statutory period
• Which patents are asserted
• Whether the generic applicant wins, loses, or settles
• Whether the settlement permits an agreed launch date
• Whether the applicant receives a first-filer or 180-day exclusivity advantage
• Whether the generic launches at risk before final patent resolution

Publicly reported settlements in branded oncology products often permit an agreed generic entry date before expiration of the latest asserted patent. Settlement terms may remain confidential or may disclose only the permitted launch date and dismissal structure.

What patent litigation affects IBRANCE?

IBRANCE litigation has centered on Paragraph IV challenges to Pfizer’s listed patents. The litigation risk is concentrated in federal district courts where Pfizer alleges infringement of palbociclib composition, formulation, or method-of-use claims.

The commercial impact of litigation depends on four outcomes:

Outcome	Impact on Pfizer
Pfizer wins all asserted claims	Generic entry remains blocked until the relevant patent barriers expire
Generic invalidates or avoids key patents	Earlier entry and accelerated price erosion
Settlement with fixed entry date	Predictable erosion but limited upside after settlement date
At-risk launch	Potential immediate volume loss, followed by damages exposure if Pfizer prevails

For valuation purposes, a settlement date often matters more than the nominal expiration of an individual patent. Multiple generic entrants can also create a sharper price decline than a single authorized or first generic entrant.

Does IBRANCE face biosimilar risk?

IBRANCE does not face biosimilar risk because palbociclib is a chemically synthesized small molecule. The relevant threat is generic substitution under the Hatch-Waxman framework, not biosimilar approval under the Biologics Price Competition and Innovation Act.

Generic manufacturers must establish pharmaceutical equivalence, bioequivalence, manufacturing compliance, and labeling conformity through an ANDA. Once approved and commercially launched, generic palbociclib can produce rapid net-price erosion through pharmacy substitution and payer management.

How does IBRANCE compare with Kisqali and Verzenio?

Attribute	IBRANCE	Kisqali	Verzenio
Active ingredient	Palbociclib	Ribociclib	Abemaciclib
Manufacturer	Pfizer	Novartis	Eli Lilly
Core disease area	HR+/HER2- breast cancer	HR+/HER2- breast cancer	HR+/HER2- breast cancer
Metastatic use	Established	Established	Established
Early-breast-cancer position	No broad adjuvant approval after negative palbociclib trials	FDA approval expanded to certain early-breast-cancer patients in 2024	Adjuvant approval for high-risk early disease
Major toxicity concern	Neutropenia	Neutropenia, QT prolongation, liver monitoring	Diarrhea, neutropenia, venous thromboembolism
Dosing pattern	Commonly 21 days on, 7 days off	Often 21 days on, 7 days off	Continuous dosing in many regimens
Key commercial advantage	Long-established metastatic franchise	Survival data and early-disease expansion	Adjuvant use and continuous dosing

Kisqali’s September 2024 FDA approval for certain patients with HR-positive, HER2-negative early breast cancer expanded its addressable market.[9] Verzenio already had an FDA-approved adjuvant role in high-risk early breast cancer.[10] These indications create pressure on IBRANCE because treatment decisions increasingly occur before metastatic disease.

IBRANCE retains advantages in physician familiarity, extensive clinical use, and a large installed patient base. Its competitive weakness is the absence of a comparable adjuvant indication.

What generic launch scenarios exist for IBRANCE?

Base case: controlled entry in the late 2020s

The most likely commercial scenario is entry by one or more generic manufacturers after negotiated settlements or final patent expirations. Pfizer would face a rapid reduction in U.S. net sales, with payer substitution and multi-source generic competition driving the largest decline.

Upside case: extended patent protection

Pfizer could preserve revenue longer if later formulation or use patents withstand litigation and block major ANDA applicants. This would delay but not eliminate eventual erosion.

Downside case: early at-risk launch

An at-risk launch could occur if a generic applicant obtains FDA approval and elects to enter before final resolution of all patent disputes. The resulting price and volume impact could precede a final judgment. This scenario carries damages and injunction risk for the generic manufacturer.

International markets will erode on different schedules because patent terms, supplementary protection certificates, national litigation, tender systems, and reimbursement rules vary by jurisdiction.

How strong is the IBRANCE patent estate?

The IBRANCE estate is commercially meaningful but mature. Its strengths are:

• Multiple patent families rather than one isolated compound patent
• Extensive regulatory and clinical-use history
• Formulation and solid-state protection
• Several potential ANDA litigation targets
• A large revenue base that supports aggressive enforcement

Its weaknesses are:

• The foundational product has been marketed for nearly a decade
• Generic applicants have strong incentives to challenge patents
• Some early patents have expired or approached expiration
• The product lacks a broad early-breast-cancer indication
• Competing CDK4/6 inhibitors have stronger recent label-expansion narratives

The estate should be valued as a declining, litigation-managed franchise rather than as a growth asset.

What is the FDA regulatory status of IBRANCE?

IBRANCE is FDA-approved for HR-positive, HER2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy, or with fulvestrant after disease progression on endocrine therapy. The FDA label also covers men and premenopausal or perimenopausal women receiving ovarian suppression.[1]

IBRANCE does not have the broad adjuvant early-breast-cancer positioning held by Verzenio or, after the 2024 label expansion, Kisqali. Pfizer’s negative PALLAS and PENELOPE-B results constrain future label-expansion potential in early disease.[6,7]

Key Takeaways

• IBRANCE generated approximately $4.8 billion in Pfizer revenue in 2024.
• Revenue has declined from roughly $5.4 billion in 2021 as the CDK4/6 market matured.
• The principal U.S. generic-entry risk is concentrated in the late 2020s, with 2027 frequently cited as a key commercial reference point.
• IBRANCE faces generic, not biosimilar, competition.
• Pfizer’s patent estate includes compound, formulation, solid-state, and method-of-use protection.
• Paragraph IV litigation and confidential or partially disclosed settlements can determine the actual launch date.
• Kisqali and Verzenio have gained strategic advantages through early-breast-cancer indications.
• IBRANCE remains a large cash-generating oncology franchise but has limited growth optionality.

FAQs

Is palbociclib still a high-revenue drug?

Yes. Pfizer reported approximately $4.8 billion in IBRANCE revenue in 2024, although sales are below the product’s earlier peak.

Is there a generic version of IBRANCE?

Broad commercial generic entry has not displaced the branded U.S. product. Generic palbociclib applicants have challenged Pfizer patents, creating late-decade launch risk.

What is the difference between IBRANCE and Kisqali?

Both are CDK4/6 inhibitors for HR-positive, HER2-negative breast cancer. Kisqali has gained a stronger recent position through overall-survival data and an FDA approval in certain early-breast-cancer patients.

What is the difference between IBRANCE and Verzenio?

IBRANCE is commonly administered on a 21-days-on, 7-days-off schedule and is associated particularly with neutropenia. Verzenio is often administered continuously and is associated particularly with diarrhea. Verzenio also has an established adjuvant indication.

Can Pfizer extend IBRANCE exclusivity with new formulations?

New formulation, crystalline-form, manufacturing, or method-of-use patents can extend protection for specific products or uses, but they do not automatically prevent all generic palbociclib entry.

References

1. U.S. Food and Drug Administration. (2024). IBRANCE (palbociclib) prescribing information.
2. Pfizer Inc. (2022). 2021 annual report.
3. Pfizer Inc. (2023). 2022 annual report.
4. Pfizer Inc. (2024). 2023 annual report.
5. Pfizer Inc. (2025). 2024 annual report.
6. Finn, R. S., Martin, M., Rugo, H. S., et al. (2021). Palbociclib and letrozole in advanced breast cancer. New England Journal of Medicine, 375, 1925-1936.
7. Loibl, S., Nitz, U., Huober, J., et al. (2021). Adjuvant palbociclib for early breast cancer. Journal of Clinical Oncology, 39, 1513-1522.
8. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
9. U.S. Food and Drug Administration. (2024). FDA approves ribociclib with an aromatase inhibitor for early breast cancer.
10. U.S. Food and Drug Administration. (2023). FDA approves abemaciclib with endocrine therapy for early breast cancer.

DrugChatter Q&A for IBRANCE

Pfizer ibrance manufactured where?
Ibrance patent expiry 2027 us?
Pfizer ibrance patent expiration us?
Ibrance generic?
What are the side effects of ibrance?